Answers are grounded in this paper and cite their sources.
Recently available evidence showed that ISBCS is an effective and cost-effective alternative to DSBCS. Nonetheless, additional (randomized) registry studies, randomized controlled trials and cost-effectiveness studies are needed to evaluate bilateral endophthalmitis rates, refractive outcomes and cost-effectiveness of ISBCS compared with DSBCS.
No takes yet. Share an insight, caveat, or question.
Spekreijse et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: